ABOUT US
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
WEBINARS
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.
-
One way to address risk related to product quality is by implementing a Question-Based Review approach. Read on to learn about this approach and its advantages.
-
Learn about the changes introduced in the latest revision to EU GMP Annex 1, and gain insight into the components that should be part of a PUPSIT risk assessment.
-
Learn about a program that has been developed to facilitate risk mitigation before process-specific filter validation is performed.
-
A partnership between Cytiva and Teva Pharmaceuticals showcases tech transfer success through effective communication, diligent project management, and a wide range of expertise.
-
Employees must have the skills to effectively execute on process development and manufacturing operations. How do you ensure they are updated on complex bioprocessing techniques and technologies?
-
Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful but also improve your chances of getting to market sooner.
-
Through an industry collaboration, Cobra and Cytiva were able to combine their expertise and experience and create a solution to meet the rising demand for high quality plasmid DNA.
-
A well-executed bioprocess technology transfer is critical to ensure smooth knowledge transfer and optimal process reproducibility.